L'intérêt à découvert pour GRI Bio donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de GRI Bio. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

GRI Bio (NASDAQ:GRI) Stock, Rapport sur les intérêts à découvert

Cohen & Steers Global Realty Majors ETF

GRI Bio

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio Inc

First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund

Grid+

GRIID Infrastructure Inc

GRINDROD SHIPPING HLDGS LTD ORD

Grin

<h3>Gainers</h3>
<ul>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares increased by 241.4% to $1.41 during Monday's regular session. The company's market cap stands at $3.6 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 224.11% to $0.8. The market value of their outstanding shares is at $5.9 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 111.91% to $4.98. The market value of their outstanding shares is at $39.7 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares moved upwards by 91.17% to $1.11. The company's market cap stands at $3.2 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares increased by 43.07% to $0.28. The company's market cap stands at $3.8 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares moved upwards by 38.8% to $6.76. The market value of their outstanding shares is at $224.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares fell 28.5% to $3.62 during Monday's regular session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock decreased by 19.17% to $0.85. The market value of their outstanding shares is at $21.6 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 18.65% to $0.04. The market value of their outstanding shares is at $4.5 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares fell 15.24% to $5.34. The market value of their outstanding shares is at $224.2 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares fell 14.53% to $14.1. The company's market cap stands at $2.2 billion. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock declined by 11.6% to $1.22. The company's market cap stands at $1.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APVO

BIVI

GNPX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRTS

HURA

MHUA

MOLN

NMRA

TCBP

WORX

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mostly lower this morning, with the Dow Jones index falling over 50 points on Monday.
Following the market opening Monday, the Dow traded down 0.13% to 43,219.80 while the NASDAQ slipped 0.01% to 18,487.82. The S&amp;P 500 also fell, dropping, 0.04% to 5,862.15.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41426981/top-4-consumer-stocks-that-may-dip-this-quarter">Top 4 Consumer Stocks That May Dip This Quarter</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate shares fell by 0.7%.
Top Headline
Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) announced that on October 11, it modified its card processing agreement to extend the deadline for its 2025 notes from October 21 to December 23 and the early maturity date from December 31 to March 3.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Genprex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares shot up 148% to $1.04.</li>
<li>Shares of GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) got a boost, surging 142% to $1.4050.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) shares were also up, gaining 125% to $2.27 after the company announced its next-generation SD7 Ultra series 5G mission-critical push-to-talk cellular radio handsets will be available on T-Mobile&#8217;s 5G network.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares dropped 22% to $4.0750.</li>
<li>Shares of JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) were down 23% to $1.61.</li>
<li>Gritstone bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) was down, falling 20% to $0.0378.</li>
</ul>
Commodities In commodity news, oil traded up 1.6% to $70.32 while gold traded up 0.8% at $2,751.70.
Silver traded up 3.5% to $34.395 on Monday, while copper rose 0.7% to $4.4150.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.7% and France's CAC 40 fell 0.7%. Spain's IBEX 35 Index fell 0.4%, while London's FTSE 100 fell 0.2%.
Producer prices in Germany fell 1.4% year-over-year in September compared to a 0.8% decline in the prior two months.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.07%, Hong Kong's Hang Seng Index dipped 1.57%, China's Shanghai Composite Index gaining 0.20% and India's BSE Sensex falling 0.09%.
The People&#8217;s Bank of China cut its one-year loan prime rate by 25bps to 3.1% at the October fixing.
Economics
No major economic reports are scheduled for release today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41427706/wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yield">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

EFSH

JDZG

SAVE

SYTA

US Stocks Edge Lower; Dow Falls 50 Points

GRI Bio Shares Resume Trade

GRI Bio Shares Halted On Circuit Breaker To The Downside, Stock Now Up 124.1%

GRI Bio Shares Resume Trade Following Circuit Breaker Halt

<h3>Gainers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares increased by 234.5% to $1.94 during Monday's pre-market session. The market value of their outstanding shares is at $5.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 56.09% to $3.67. The company's market cap stands at $29.2 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 45.1% to $0.13. The company's market cap stands at $1.4 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares moved upwards by 35.36% to $2.22. The market value of their outstanding shares is at $34.1 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 25.05% to $6.09. The market value of their outstanding shares is at $202.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 23.72% to $1.13. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock declined by 18.4% to $0.04 during Monday's pre-market session. The company's market cap stands at $4.5 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) stock decreased by 10.37% to $0.45. The market value of their outstanding shares is at $15.2 million. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) shares fell 10.05% to $6.36. The company's market cap stands at $2.4 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 10.01% to $0.99. The company's market cap stands at $2.8 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares declined by 9.97% to $2.62. The market value of their outstanding shares is at $2.2 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) shares declined by 9.04% to $2.77. The company's market cap stands at $28.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

LFST

LGMK

MNDR

PHIO

VSEE

WINT

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock increased by 234.5% to $1.94 during Monday's pre-market session. The market value of their outstanding shares is at $5.6 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 56.09% to $3.67. The market value of their outstanding shares is at $29.2 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 45.1% to $0.13. The market value of their outstanding shares is at $1.4 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock moved upwards by 35.36% to $2.22. The market value of their outstanding shares is at $34.1 million. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 25.05% to $6.09. The market value of their outstanding shares is at $202.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 23.72% to $1.13. The market value of their outstanding shares is at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) stock decreased by 18.4% to $0.04 during Monday's pre-market session. The company's market cap stands at $4.5 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares decreased by 10.37% to $0.45. The company's market cap stands at $15.2 million. </li>
<li>LifeStance Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFST#NASDAQ">LFST</a>) stock fell 10.05% to $6.36. The market value of their outstanding shares is at $2.4 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares fell 10.01% to $0.99. The market value of their outstanding shares is at $2.8 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares decreased by 9.97% to $2.62. The market value of their outstanding shares is at $2.2 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock fell 9.04% to $2.77. The market value of their outstanding shares is at $28.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) rose sharply in today's pre-market trading.
Spirit Airlines announced that on October 11, it modified its card processing agreement to extend the deadline for its 2025 notes from October 21 to December 23 and the early maturity date from December 31 to March 3.
Spirit Airlines shares jumped 43.5% to $2.11 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) rose 151.2% to $1.46 in pre-market trading after jumping around 19% on Friday. GRI Bio, last week, announced it presented preclinical data highlighting GRI-0621&#8217;s ability to inhibit invariant natural killer T cell activity.</li>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) gained 98.7% to $4.67 in pre-market trading after jumping around 110% on Friday.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares surged 60% to $4.48 in pre-market trading after declining 8% on Friday.</li>
<li>Genprex, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) rose 42.7% to $0.5980 in pre-market trading after gaining around 21% on Friday. Genprex recently announced it has advanced to the highest dose group in its Acclaim-3 trial for Reqorsa Gene Therapy with Tecentriq after receiving a safety review committee approval.</li>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares jumped 37.2% to $2.25 in pre-market trading after gaining around 18% on Friday.</li>
<li>Aptevo Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares rose 16.6% to $0.2317 in pre-market trading after jumping around 24% on Friday.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) gained 16.1% to $0.4640 in pre-market trading after dipping 43% on Friday.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) climbed 15.2% to $5.82 in pre-market trading.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) gained 15.2% to $0.1001 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares dipped 24.7% to $3.96 in pre-market trading after jumping around 199% on Friday.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares fell 21.5% to $1.64 in pre-market trading after jumping 23% on Friday.</li>
<li>Agrify Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) fell 12.7% to $3.61 in today's pre-market trading after jumping over 25% on Friday.</li>
<li>Molecular Templates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) fell 11.3% to $0.6651 in pre-market trading after dipping 19% on Friday.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) shares declined 11.1% to $2.09 in pre-market trading after gaining over 4% on Friday.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 8.7% to $3.78 in pre-market trading after jumping over 20% on Friday.</li>
<li>Qilian International Holding Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) shares declined 8.7% to $7.00 in pre-market trading.</li>
<li>Zapata Computing Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) fell 8% to $0.0865 in pre-market trading after declining around 10% on Friday.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) declined 7.2% to $2.70 in pre-market trading after jumping 10% on Friday.</li>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) shares fell 5.6% to $0.8580 after jumping 106% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

News

Pre-Market Outlook

AGFY

MTEM

NKGN

SHLS

TNON

VSME

VTAK

XPON

ZPTA

Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock rose 66.5% to $2.73 during Friday's after-market session. The company's market cap stands at $41.9 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock moved upwards by 21.58% to $0.71. The company's market cap stands at $2.0 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares moved upwards by 5.67% to $1.49. The market value of their outstanding shares is at $20.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 5.49% to $0.44. The company's market cap stands at $10.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 5.14% to $0.09. The market value of their outstanding shares is at $4.6 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares moved upwards by 5.0% to $0.9. The market value of their outstanding shares is at $91.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares fell 7.8% to $2.86 during Friday's after-market session. The market value of their outstanding shares is at $26.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 7.21% to $0.44. The market value of their outstanding shares is at $2.4 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 7.03% to $0.79. The market value of their outstanding shares is at $3.1 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares declined by 6.45% to $0.47. The market value of their outstanding shares is at $14.0 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 6.2% to $0.7. The company's market cap stands at $4.6 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock decreased by 5.81% to $2.11. The market value of their outstanding shares is at $62.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CERO

HCTI

IMRX

KZIA

QNRX

SABS

TLSA

12 Health Care Stocks Moving In Friday's After-Market Session

WIIM

GRI Bio shares are trading higher after the company announced it presented preclinical data highlighting GRI-0621's ability to inhibit invariant natural killer T cell activity.

Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis &nbsp;
Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q4 2024 and topline data in Q1 2025
Data presented at the 22nd International Colloquium on Lung and Air

GRI Bio Presents Preclinical Data Highlighting GRI-0621's Ability To Inhibit Invariant Natural Killer T Cell Activity

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 123.5% to $0.85 during Monday's pre-market session. The market value of their outstanding shares is at $144.7 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares increased by 67.19% to $3.16. The market value of their outstanding shares is at $165.4 million. </li>
<li>Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) stock rose 51.28% to $58.85. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares rose 18.18% to $2.6. The company's market cap stands at $14.8 million. </li>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) stock increased by 15.05% to $17.27. The market value of their outstanding shares is at $260.8 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares rose 13.86% to $2.3. The market value of their outstanding shares is at $67.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares declined by 78.5% to $0.32 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 16.77% to $0.82. The market value of their outstanding shares is at $8.2 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares declined by 11.9% to $3.63. The company's market cap stands at $4.8 million. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares declined by 8.87% to $26.0. The market value of their outstanding shares is at $790.6 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock decreased by 7.74% to $0.37. The market value of their outstanding shares is at $1.0 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 7.65% to $0.43. The market value of their outstanding shares is at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DWTX

HSTM

IMRN

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

LBPH

NIVF

RANI

TVGN

VRPX

<h3>Gainers</h3>
<ul>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares rose 63.7% to $2.98 during Tuesday's pre-market session. The company's market cap stands at $9.5 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock rose 51.53% to $1.29. The market value of their outstanding shares is at $3.2 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 34.8% to $0.19. The company's market cap stands at $5.1 million. </li>
<li>ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares moved upwards by 15.35% to $17.8. The market value of their outstanding shares is at $490.7 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock increased by 15.18% to $0.4. The market value of their outstanding shares is at $1.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares rose 12.17% to $0.58. The market value of their outstanding shares is at $1.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock decreased by 15.5% to $0.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $18.2 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock fell 11.57% to $5.94. The company's market cap stands at $362.7 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 10.64% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 9.59% to $0.49. The market value of their outstanding shares is at $8.4 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 9.24% to $0.29. The market value of their outstanding shares is at $49.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 8.83% to $1.24. The company's market cap stands at $11.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

ENTO

OTRK

RNAZ

SAGE

TRIB

VINC

VIRI

ZIMV

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/DOCU/news">pre-market trading</a>.
DocuSign will replace MDU Resources Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDU#NYSE">MDU</a>) in the S&amp;P MidCap 400, effective prior to the opening of trading on Friday, Oct. 11.
DocuSign shares jumped 5.7% to $66.35 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) rose 98.8% to $0.2699 in pre-market trading after dipping 6% on Monday.</li>
<li>Ontrak, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) rose 63.7% to $2.98 in pre-market trading after declining around 7% on Monday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) gained 52.1% to $0.6801 in pre-market trading after the company secured $65 million financing from Liqueous LP, to accelerate commercialization.</li>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares rose 47.3% to $0.4998 in pre-market trading. Ascendiant Capital analyst Edward Woo initiated coverage on GRI Bio with a Buy rating and announced a price target of $12.</li>
<li>Virios Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) shares gained 27% to $0.1750 in pre-market trading after dipping around 20% on Monday. Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. announced business combination to form Dogwood Therapeutics, Inc.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares surged 18.1% to $0.4680 in pre-market trading after dipping over 5% on Monday.</li>
<li>Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) shares jumped 11.8% to $29.09 in pre-market trading. HC Wainwright &amp; Co. analyst Mitchell Kapoor, on Monday, initiated coverage on Oruka Therapeutics with a Buy rating and announced a price target of $45.</li>
<li>Mama&#8217;s Creations, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) gained 9.9% to $9.00 in pre-market trading.</li>
<li>Lytus Technologies Holdings PTV. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>) shares gained 9.1% to $1.80 in pre-market trading after declining 4% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares dipped 34.2% to $6.65 in pre-market trading after the company raised $8.2 million in private placement with institutional investors.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) fell 27.8% to $0.9878 in today's pre-market trading after dipping 32% on Monday.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares fell 23.5% to $5.20 in pre-market trading after gaining 35% on Monday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares declined 23% to $3.59 in pre-market trading after gaining around 25% on Monday.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) fell 21.4% to $0.4720 in pre-market trading after gaining 28% on Monday.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares fell 20.1% to $0.4615 in pre-market trading.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) shares fell 19.2% to $2.98.</li>
<li>Futu Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) shares declined 18.6% to $104.90 in pre-market trading.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) fell 16.6% to $0.2333 in pre-market trading after declining 5% on Monday.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) declined 14.2% to $0.84 in pre-market trading after dipping around 7% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41221716/dow-dips-around-400-points-as-treasury-yields-top-4-investor-optimism-declines-but-fear-index-remai">Dow Dips Around 400 Points As Treasury Yields Top 4%: Investor Optimism Declines, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

BURU

CETX

DBGI

DOCU

FUTU

MAMA

NMHI

OGEN

ORKA

RIME

SOBR

Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Ascendiant Capital analyst Edward Woo initiates coverage on GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) with a Buy rating and announces Price Target of $12.

Price Target

Initiation

Analyst Ratings

Ascendiant Capital Initiates Coverage On GRI Bio with Buy Rating, Announces Price Target of $12

<h3>Gainers</h3>
<ul>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 38.8% to $13.82 during Monday's regular session. The company's market cap stands at $488.1 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) shares moved upwards by 36.58% to $0.74. The company's market cap stands at $54.2 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 32.73% to $0.47. The company's market cap stands at $35.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock rose 27.82% to $4.87. The company's market cap stands at $7.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock increased by 16.44% to $4.03. The company's market cap stands at $483.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock moved upwards by 16.35% to $0.59. The market value of their outstanding shares is at $22.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 28.8% to $0.46 during Monday's regular session. The company's market cap stands at $6.0 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares declined by 27.4% to $0.67. The company's market cap stands at $6.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 25.87% to $0.36. The company's market cap stands at $2.6 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 20.04% to $1.48. The company's market cap stands at $8.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 19.87% to $16.07. The market value of their outstanding shares is at $864.0 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 18.81% to $0.36. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

BNOX

CAPR

HCWB

PRME

PRTA

PSTV

XBIO

GRI Bio shares are trading lower. The company announced it has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application No. 2023-000750 titled, "Prevention and Treatment of Inflammatory Conditions."

Legal

GRI Bio Granted Japan Patent For No. 2023-000750 Titled, "Prevention and Treatment of Inflammatory Conditions."

MHRA and HREC authorization in Australia further expands and will potentially accelerate enrollment in ongoing U.S. and UK Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF")
Company on track to report interim data Q4 2024 and topline data Q1 2025
LA JOLLA, CA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the authorization of its Clinical Trial Application (CTA) by the Australian Medicines and Healthcare products Regulatory Agency (MHRA) and the Human Research Ethics Committee (HREC) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in Australia.

Biotech

General

GRI Bio Receives Authorization To Conduct Phase 2a Biomarker Study Evaluating GRI-0621 In Australia; Company On Track To Report Interim Data Q4 2024 And Topline Data Q1 2025

GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) reported quarterly losses of $(4.92) per share. This is a 97.94 percent increase over losses of $(239.37) per share from the same period last year.

GRI Bio Q2 EPS $(4.92) Up From $(239.37) YoY

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Taysha Gene Therapies&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsha-stock-quote/">TSHA</a>) stock is taking a beating on Wednesday after the gene therapy company announced a <a href="https://www.nasdaq.com/press-release/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-funded">proposed public offering</a> for its shares.



Taysha Gene Therapies says that it intends to offer up to $75 million worth of TSHA stock in this offering. The company hasn&rsquo;t nailed down how many shares will be included or what they will be priced at.



What we do know is that it also intends to offer pre-funded warrants for certain investors. On top of that, underwriters have a 30-day option to acquire an additional 15% of shares included in the offering.



Jefferies and Goldman Sachs &amp; Co. LLC are serving as joint book-running managers for the public offering. Cantor is acting as a book-running manager for it as well.



<h2>How This Affects TSHA Stock</h2>



With this public offering will come an increase in the number of TSHA shares on the market. Doing this dilutes the stakes of current investors in the company. That&rsquo;s one of the reasons why the shares are falling today.



On top of that, the pricing of the offering may upset investors. It&rsquo;s expected to be discounted compared to the company&rsquo;s prior closing price. If so, that will likely have a further negative effect on the company&rsquo;s shares.



TSHA stock is down 14% as of Wednesday morning.



There are plenty of other stock market stories traders are going to want to read about today!



We have all of the hottest stock market stories ready to go on Wednesday! That includes all of the latest news from GRI Bio&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>), Anew Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) and Syntec Optics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/optx-stock-quote/">OPTX</a>). You can read up on all of these matters at the following links!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-gri-bio-gri-stock-down-29-today/">Why Is GRI Bio (GRI) Stock Down 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-anew-medical-wena-stock-up-144-today/">Why Is Anew Medical (WENA) Stock Up 144% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-syntec-optics-optx-stock-up-186-today/">Why Is Syntec Optics (OPTX) Stock Up 186% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-taysha-gene-therapies-tsha-stock-down-14-today/">Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?

GRI Bio announces pricing of $4 million public offering

GRI Bio regains compliance with Nasdaq

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!



Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chuy&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/chuy-stock-quote/">CHUY</a>) stock is rocketing more than 46% on a <a href="https://www.nasdaq.com/press-release/darden-restaurants-acquire-chuys-holdings-inc-approximately-605-million-transaction">$605 million acquisition deal</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) shares are soaring over 43% alongside heavy pre-market trading.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is surging more than 25% with strong early morning trading.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are rising over 23% as it <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">kicks off a Phase 3 clinical trial</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is increasing more than 18% with strong pre-market trading.</li>



<li>ZimVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/zimv-stock-quote/">ZIMV</a>) shares are heading over 13% higher without any clear news on Thursday morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is gaining more than 12% on a <a href="https://www.globenewswire.com/news-release/2024/07/18/2914992/0/en/SAI-TECH-Global-Corporation-Announces-Share-Repurchase-Program.html">share repurchase program</a>.</li>



<li>MultiMetaVerse (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmv-stock-quote/">MMV</a>) shares are climbing over 11% as it continues a recent rally.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is jumping more than 10% despite a lack of news today.</li>



<li>XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) shares are up over 10% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Leslies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lesl-stock-quote/">LESL</a>) stock is diving more than 21% on <a href="https://www.nasdaq.com/press-release/leslies-inc-announces-preliminary-third-quarter-fiscal-2024-financial-results-and">preliminary earnings and guidance</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rumbling over 13% after a massive rally yesterday.</li>



<li>Domino&rsquo;s Pizza (NYSE:<a href="https://investorplace.com/stock-quotes/dpz-stock-quote/">DPZ</a>) stock is sliding more than 13% with the release of its <a href="https://ir.dominos.com/static-files/68ecdbfc-bd1c-486a-a574-d6f54b7e5132">Q2 earnings report</a>.</li>



<li>CBL International (NASDAQ:<a href="https://investorplace.com/stock-quotes/banl-stock-quote/">BANL</a>) shares are taking an over 12% beating on Thursday morning as it retreats from a rally yesterday.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) stock is dropping close to 12% after an unexpected rally yesterday.</li>



<li>Beyond Meat (NASDAQ:<a href="https://investorplace.com/stock-quotes/bynd-stock-quote/">BYND</a>) shares are falling more than 11% on <a href="https://www.wsj.com/articles/beyond-meat-engages-bondholders-for-restructuring-talks-7de6b8ae">restructuring talks with bondholders</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is decreasing over 11% this morning after rallying on Wednesday.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are slipping more than 10% <a href="https://investorplace.com/2024/07/why-is-aditxt-adtx-stock-up-72-today/">following a rally yesterday</a>.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is dipping over 10% <a href="https://investorplace.com/2024/07/stardust-power-sdst-stock-pops-140-days-after-debut-what-to-know/">after a surprise rally yesterday</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are not for everyone, let&rsquo;s make that perfectly clear. It&rsquo;s challenging to invest in a field in which companies &ndash; particularly startups &ndash; can go for years without seeing a penny of revenue. 



While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get in too much trouble.



Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and technologies, working in the fields of gene therapy, personalized medicine and biologics.



The challenge in this sector is that it takes a long time to bring a new drug or therapy to market. 



Even after the drug or therapy is discovered and developed in a laboratory setting, biotech companies must undergo preclinical research and a series of clinical trials. All these trials must be successful to go to the next step in the process. 



Clinical trials can often be expensive and time-consuming. And if the drug or therapy passes all of that, it still needs to get approval from the Food and Drug Administration (and regulators in other countries) before it can be brought to market.



Well-established biotech companies that have a history of success can better withstand these issues if they&rsquo;ve previously brought drugs to market and are bringing in revenue. 



But for a new company that doesn&rsquo;t have a revenue stream, clinical trials can try the patience of any investor &ndash; particularly as a company goes deeper into debt.



The biotech stocks we&rsquo;re looking at today all have good ideas, but the hurdles they have to clear to turn the corner are extremely high. 



If you&rsquo;re going to invest in the biotech sector, you should consider avoiding these names &ndash; and if you&rsquo;re an investor, you should take this opportunity to recognize biotech stocks to sell now.



<h2>Ginkgo Bioworks (DNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600-300x169.png" alt="Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock"><div>Source: T. Schneider / Shutterstock.com</div></div>Ginkgo Bioworks (NYSE:<a href="https://investorplace.com/stock-quotes/dna-stock-quote/">DNA</a>) is a Boston-based company that uses genetic engineering to produce bacteria with industrial applications for other biotech companies.



The company specializes in cell programming and biosecurity. It&rsquo;s <a href="https://finance.yahoo.com/news/ginkgo-bioworks-novo-nordisk-expand-110200616.html">working</a> with Dutch biotech company Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) on several research and development projects over the next five years, including diabetes and obesity medications.



Ginkgo also <a href="https://www.syngenta.com/en/company/media/syngenta-news/year/2024/syngenta-collaborates-ginkgo-bioworks-enable-faster-launch">announced</a> a collaboration with agricultural company Syngenta to develop and optimize a microbial strain for a secondary metabolite in Syngenta&rsquo;s pipeline.



As promising as these sound, the reality doesn&rsquo;t match up. DNA stock is down 82% this year and the company has just been trying to maintain its New York Stock Exchange <a href="http://investors.ginkgobioworks.com/news/news-details/2024/Ginkgo-Bioworks-Receives-Continued-Listing-Standard-Notice-From-NYSE/default.aspx">listing compliance</a>.



The company also instituted deep staff cuts, <a href="https://investorplace.com/2024/06/ginkgo-bioworks-layoffs-expand-to-400-job-cuts/">laying off</a> at least 35% of its 1,200-member workforce. &nbsp;



Revenue in the first quarter was $38 million, down from $81 million in the first quarter of 2023. Overall, the company reported a loss of $178 million for the quarter.



DNA stock gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/txnp-stock-quote/">TXNP</a>) is making drugs and therapies to treat central nervous system disorders. But like many other biotech companies, it&rsquo;s paying the bills is a challenge.



Tonix hasn&rsquo;t yet brought a drug to market. It does have a candidate in Phase 3 testing as a treatment for fibromyalgia. The company is hoping for FDA approval for its drug, Tonmya, in the second half 2025.



Tonix also has a therapy in Phase 2 trials that would treat long Covid-19 symptoms, but Tonmya is much closer to becoming a reality.



That&rsquo;s why the company&rsquo;s trying to raise money. It had&nbsp;<a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1490/tonix-pharmaceuticals-announces-closing-of-4-0-million">two separate $4 million public offerings in June</a>&nbsp;that will help, but also served to dilute investor equity. It also completed a 1-for-32 reverse stock split to regain Nasdaq listing compliance.



Tonix recorded a <a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1469/tonix-pharmaceuticals-reports-first-quarter-2024-financial">net loss of $14.9 million in the first quarter,</a>&nbsp;or 18 cents per share. It only had $7 million in cash on hand at the end of the quarter, so it needs all the money it can get from its fundraising efforts.



TNXP stock is already back below $1 per share, having dropped 93% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



Tonix stock is down 95% this year, getting an &ldquo;F&rsquo; rating in the Portfolio Grader.



<h2>Gain Therapeutics (GANX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>Gain Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ganx-stock-quote/">GANX</a>) is a Maryland company that is developing possible therapies for neurodegenerative diseases, genetic disorders and cancer. 



The company lead candidate, which is in Phase 1 trials, has the potential to treat Parkinson&rsquo;s disease and other neurodegenerative diseases such as Gaucher disease, and Alzheimer&rsquo;s disease.



Gain also has a drug discovery platform called Magellan that uses artificial intelligence to help it develop therapies.



It&rsquo;s also trying to raise money, although doing so isn&rsquo;t a good deal for current shareholders. 



<a href="https://investorplace.com/2024/06/why-is-gain-therapeutics-ganx-stock-down-25-today/">Last month</a> it sold 7.11 million shares at $1.35 each in an effort to raise $11 million so it can continue testing its lead drug candidate. But the public offering also increased the number of shares in the company, which diluted shares.



It&rsquo;s also notable that CEO Matthias Alder abruptly left Gain in late June. He was replaced on an interim basis by Gene Mack, the chief financial officer.



All in all, Gain appears not to be on firm footing and is a long way from seeing revenue from its top drug candidate. The stock is down 62% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>GlycoMimetics (GLYC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) is another Maryland company. It&rsquo;s working on developing glycobiology-based therapies for cancer and inflammatory disease.



Glycobiology involves working with carbohydrates or sugar chains in an effort to develop appropriate therapies.



But the company took a major hit this spring when Phase 3 trials of its lead drug candidate failed to be statistically significant. The drug, uproleselan, was bring developed for the treatment of relapsed/refractory acute myeloid leukemia.



The company <a href="https://www.nasdaq.com/press-release/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed">noted</a> that the study didn&rsquo;t &ldquo;achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.&rdquo; 



Patient survival reached a median of 13 months as compared to 12.3 months just with chemotherapy.



The company said it&rsquo;s planning to meet with regulators and the National Cancer Institute to determine a path forward. Meanwhile, the floor has fallen out from GLYC stock, which is down 87% on the year. It gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>GRI Bio (GRI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) is developing therapies to treat inflammatory disease. 



Its&nbsp;therapies would target the activity of Natural Killer T (&ldquo;NKT&rdquo;) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression.



The company has four drug candidates in its pipeline, with the most advanced being a treatment for idiopathic pulmonary fibrosis. That candidate is in Phase 2 trials.



Like many other early-stage biotech companies, GRI Bio is trying to raise money to keep the doors open, while at the same time <a href="https://gribio.com/gri-bio-regains-compliance-with-nasdaq/">trying not to be delisted by the index</a>.



The company announced late last month that it would sell more than 2 million shares of GRI stock &ndash; an <a href="https://investorplace.com/2024/06/why-is-gri-bio-gri-stock-down-29-today/">announcement</a> that sent the stock price down by 29%.



GRI stock is now down 95% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Ovid Therapeutics (OVID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Ovid Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ovid-stock-quote/">OVID</a>) is a biotech company that is working to create therapies to combat neurological diseases. 



Its drug candidate to treat brainstem malformations completed Phase 1 trials, while three other drug candidates are not as far advanced.



Ovid also has a partnership with Takeda to bring another drug, soticlestat to market to treat Dravet syndrome and Lennox-Gastaut syndrome. 



Both therapies are in Phase 3 trials, but the top-line study results are not promising. 



The treatment for Dravet syndrome narrowly missed its primary endpoint in reducing the frequency of seizures, and its treatment for Lennox-Gastaut syndrome missed its mark in reducing motor drop seizures.



Ovid only had revenue of <a href="https://investors.ovidrx.com/news/news-details/2024/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2024-Financial-Results/default.aspx">$148,000 in the first quarter</a> versus operating expenses of $17.2 million. The company has roughly $90 million of cash on hand, so it&rsquo;s not at immediate risk. But it&rsquo;s also a long way from turning a profit as well.



OVID stock is down 70% this year &ndash; with much of that drop coming after the Phase 3 trials on soticlestat were released. and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>Cosmos Health (<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Cosmos Health (NASDASQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) is a Chicago company that serves as a holding company. 



Its portfolio includes pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept.



The company also operates a subsidiary, Cana Laboratories, to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. 



The company makes and sells branded generics and over-the-counter medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the U.K.



The company has not yet filed its fourth-quarter report, and received a notice of noncompliance from Nasdaq for the failure. 



But its third-quarter report included a couple of red flags, including a drop in year-to-date revenue from $38.3 million to $37.5 million; and a drop in cash from $20.7 million to $2.3 million.



COSM stock is down 10% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier had a long position in NVO. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/07/7-sorry-biotech-stocks-set-to-make-investors-sad-2/">7 Sorry Biotech Stocks Set to Make Investors Sad</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Sorry Biotech Stocks Set to Make Investors Sad

GRI Bio (GRI) has provided an announcement. The provided information, including any exhibits, is for informational purposes only and should not be ...

GRI Bio Shares Informational Update Not for Legal Use

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) just reported results for the second quarter of 2024.<ul><li>GRI Bio reported earnings per share of -$4.92.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/gri-stock-earnings-gri-bio-for-q2-of-2024/">GRI Stock Earnings: GRI Bio Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GRI Stock Earnings: GRI Bio Reported Results for Q2 2024

GRI Bio reports Q2 results

Warning: GRI is at high risk of performing badly

ADTX

APLM

AREB

BANL

BYND

CHUY

COSM

GANX

GLYC

LESL

ONCO

OPTX

OVID

SDST

TSHA

WENA

WIMI

XWEL

Press Releases

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio Participates in Virtual Investor KOL Connect Segment

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVI – Must-Watch Stocks This Week

Comments

GRI Bio

Intérêt court

GRI Bio (NASDAQ:GRI) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL